Why AIROS Medical’s extended warranty could reshape buyer expectations in lymphedema care
Find out how AIROS Medical’s five-year warranty on compression devices may shift durability standards and procurement expectations in lymphedema care.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
GT Medical Technologies’ BRIDGES trial begins enrollment, testing GammaTile in newly diagnosed glioblastoma patients
GT Medical Technologies has announced the first patient enrollments in its BRIDGES trial, a randomized clinical study assessing the use of GammaTile therapy in newly diagnosed glioblastoma. The trial introduces GammaTile at the time of initial tumor resection, marking a notable shift from the conventional glioblastoma radiation timeline, which typically delays radiation until several weeks
Medical Devices & Diagnostics
Robotic cochlear implants approved for kids: Is iotaSOFT reshaping pediatric ENT standards?
iotaMotion, Inc. has received U.S. Food and Drug Administration 510(k) clearance to expand the approved use of its iotaSOFT Robotic-Assisted Cochlear Implant Insertion System for children as young as four years old. This regulatory milestone makes the iotaSOFT system the first robotic-assisted cochlear insertion platform authorized for use in school-aged pediatric patients, expanding access to
Medical Devices & Diagnostics
Vista AI raises $29.5m to expand automated MRI scanning beyond cardiology
Vista AI, a U.S.-based medical imaging software company specializing in AI-powered MRI automation, has raised $29.5 million in Series B financing to accelerate its product roadmap and scale adoption across U.S. hospitals and imaging centers. The funding round, announced on January 14, 2026, includes strategic investments from leading health systems such as Cedars-Sinai Health System,
Medical Devices & Diagnostics
Illumina’s Billion Cell Atlas marks inflection point for AI-enabled drug discovery in 2026
Illumina, Inc. has launched the Billion Cell Atlas, a large-scale genetic perturbation dataset designed to serve as foundational infrastructure for artificial intelligence-enabled drug discovery. Announced alongside strategic collaborations with AstraZeneca, Merck, and Eli Lilly and Company, the platform leverages CRISPR-based genome editing and single-cell RNA sequencing across more than 200 disease-relevant cell lines. This marks
Medical Devices & Diagnostics
Smith+Nephew bets on lower failure rates in shoulder surgery with $450m Integrity Orthopaedics acquisition
Smith+Nephew has signed a definitive agreement to acquire Integrity Orthopaedics, a U.S.-based developer of the Tendon Seam rotator cuff repair system, in a deal worth up to $450 million. The move strengthens the medical device manufacturer’s presence in the sports medicine market by adding a novel repair platform designed to reduce re-tear rates, improve workflow
Medical Devices & Diagnostics
FDA clears 3DICOM MD Cloud: What this means for Singular Health’s U.S. expansion and diagnostic imaging disruption
The U.S. Food and Drug Administration has granted 510(k) clearance to Singular Health Limited’s 3DICOM MD Cloud platform, expanding the Australian company’s regulated product portfolio in the United States. This marks the second FDA approval for the company’s medical imaging software line, following the clearance of its desktop-based 3DICOM MD Viewer in October 2022. The
Medical Devices & Diagnostics
What the first use of YorLabs’ ICE device tells us about cardiology imaging disruption
Find out how YorLabs’ FDA-cleared ICE platform could transform electrophysiology access and imaging economics in 2026.
Medical Devices & Diagnostics
Why 10x Genomics is betting on peripheral blood to decode complex immune disorders
Find out how 10x Genomics and Brigham & Women's Hospital are using single-cell profiling to redefine autoimmune diagnostics. Can it change patient care?
Medical Devices & Diagnostics
Why Theradaptive’s OsteoAdapt could disrupt the $2bn spinal biologics market in 2026
ATEC secures U.S. rights to Theradaptive’s OsteoAdapt. Find out what this deal changes for spinal biologics in 2026 and beyond.